Two People Die After Paid Plasma Donation at Clinics in Canada

Two people have died in Canada after giving plasma at for‑profit donation clinics, prompting a federal probe and renewed debate over donor safety, industry regulation, and the ethics of paid plasma collection. The deaths—described by officials as “fatal adverse reactions”—occurred months apart and involved the same chain of clinics operating under a private model that compensates donors.
Health Canada, the federal department responsible for regulating plasma donation centers, confirmed it has received reports of two deaths connected to plasma collection procedures at for‑profit clinics in Winnipeg, Manitoba. The first occurred in October 2025, and the second in January 2026. Both deaths are now the subject of active review by federal inspectors as authorities seek to determine whether the procedures or equipment used contributed to the incidents.
Officials have not publicly identified the individuals involved, but friends of one victim told local media she was a 22‑year‑old international student who was donating plasma when she suddenly went into distress and subsequently died.
The clinics where the donations took place are operated by the Spanish healthcare company Grifols, which runs approximately 17 paid plasma donation centers nationwide. Grifols has stated it is cooperating with Health Canada’s investigation, and insists it “has no reason to believe there is a correlation” between the deaths and the plasma donation process.
How Paid Plasma Donation Works in Canada
Plasma—the liquid component of blood—contains proteins essential for manufacturing medicines that treat conditions such as hemophilia, immune deficiencies, and certain neurological disorders. Unlike whole blood, plasma can be donated more frequently because the other components are returned to the donor’s body during the procedure.
Until recently, paid plasma donation was illegal in several parts of Canada. However, starting in the early 2020s, Grifols entered into agreements with Canadian Blood Services and provincial health authorities that allow the company to offer financial compensation—typically up to about C$100 per visit—to donors in select provinces including Manitoba and Saskatchewan.
The arrangements have expanded as domestic demand for plasma products has grown. Canadian Blood Services notes that local plasma collection still only meets a fraction of the country’s need for these critical medical materials.
While voluntary (unpaid) blood and plasma donation remains the standard in provinces such as Quebec and British Columbia, paid plasma centers have opened in others under regulatory exemptions and agreements designed to boost supply. The practice is controversial, with advocates for a voluntary system warning that payments can encourage frequent or risky donation behavior among donors who may be financially vulnerable.
Investigation and Safety Concerns
Health Canada has dispatched inspectors to the Winnipeg clinics following the reported fatalities. Preliminary information indicates that both incidents occurred during or shortly after individuals underwent the standard plasma donation process, and were categorized by authorities as “fatal adverse reactions,” requiring mandatory reporting to the federal regulator.
Regulatory records for the clinics have also drawn scrutiny. Recent inspections in provinces where Grifols operates identified deficiencies including incomplete record‑keeping, lapses in donor screening, and inconsistent maintenance of equipment—issues that raise questions about compliance with the Food and Drugs Act and federal blood regulations.
Critics argue that the string of problems, including two deaths, illustrates deeper structural weaknesses in how paid plasma donation is overseen. “When you have a private company operating these clinics, you lose control over much of the industry,” said a blood safety advocate. “Public accountability and transparency should be paramount when people’s lives are literally at stake.”
For many Canadians, memories of the tainted blood scandal of the 1980s—when thousands were infected with HIV and hepatitis C through contaminated blood products—still loom large. That crisis led to major reforms and strict safeguards to protect donors and recipients. Some experts fear the renewed reliance on paid, private plasma collection may erode that hard‑won trust in the system.
Response
Grifols has reaffirmed that it follows stringent screening protocols and that donors undergo health evaluations before each appointment. The company says it has implemented corrective plans to address any non‑compliance identified by inspectors and is focused on preventing future issues.
Canadian Blood Services expressed sorrow over the deaths but emphasized that safety remains its highest priority. The national body highlighted that plasma donation, when properly regulated and monitored, is generally considered safe and that serious adverse reactions are rares.
Patient advocates and public health groups, however, are calling for greater transparency and stricter oversight. With paid plasma donation still a relatively new phenomenon in Canada, many are urging regulators to release more detailed information on the causes of the deaths and whether systemic changes are needed to protect donors.
What Happens Next
Health Canada’s investigation could take weeks or months to complete as officials review medical records, equipment logs, and operational procedures at the affected clinics. If regulatory breaches are found to have contributed to the fatalities, authorities could impose penalties, require corrective action plans, or even suspend operations at the centers.
For now, the tragic deaths underscore the importance of robust safety standards in medical donation settings and have reignited debate over the role and regulation of for‑profit clinics in Canada’s blood and plasma landscape.